@article{66413e8ddba64666bc2f852a1c84a9b4,
title = "Executive summary: The management of community-acquired pneumonia in infants and children older than 3 months of age: Clinical practice guidelines by the pediatric infectious diseases society and the infectious diseases society of America",
abstract = "Evidenced-based guidelines for management of infants and children with community-acquired pneumonia (CAP) were prepared by an expert panel comprising clinicians and investigators representing community pediatrics, public health, and the pediatric specialties of critical care, emergency medicine, hospital medicine, infectious diseases, pulmonology, and surgery. These guidelines are intended for use by primary care and subspecialty providers responsible for the management of otherwise healthy infants and children with CAP in both outpatient and inpatient settings. Site-of-care management, diagnosis, antimicrobial and adjunctive surgical therapy, and prevention are discussed. Areas that warrant future investigations are also highlighted.",
author = "Bradley, {John S.} and Byington, {Carrie L.} and Shah, {Samir S.} and Brian Alverson and Carter, {Edward R.} and Christopher Harrison and Kaplan, {Sheldon L.} and MacE, {Sharon E.} and McCracken, {George H.} and Moore, {Matthew R.} and {St Peter}, {Shawn D.} and Stockwell, {Jana A.} and Swanson, {Jack T.}",
note = "Funding Information: S. S. S. receives research support from the National Institutes of Health and the Robert Wood Johnson Foundation. He received past research support from Wyeth Pharmaceuticals (completed September 2009); the funding was to his employer. All other authors: No reported conflicts. Funding Information: Potential conflicts of interest. J. S. B. has received no pharmaceutical funding or support during the past 36 months for management of pediatric CAP. C. L. B. served as principal investigator on Wyeth/Pfizer clinical trials of PCV13; the funding was to her employer, the University of Utah. C. H. has received honoraria from Sanofi Pasteur, and his employer has received grant funds for research performed by C. H. from Johnson & Johnson Pharmaceuticals, Cubist, Merck, Sanofi Pasteur, Astellas, and GlaxoSmithKline. S. L. K. has served as a consultant for Pfizer, GlaxoSmithKline, and Novartis. S. E. M. has served as principal investigator on a Gebauer clinical trial for vapocoolant and a clinical site investigator for a multicenter Baxter Hylenex clinical trial, the funding for both trials was to her employer, the Cleveland Clinic; she has also served as consultant for Baxter Health Care, Halozyme Therapeutics, Pricara (Ortho-McNeil-Janssen), Rox-888, and Venasite. J. A. S. has given expert testimony for Finley, Alt, Smith, and Schamberg. Funding Information: The recommendations in this report do not represent an official document of the Centers for Disease Control and Prevention. Financial support. This work was supported by the IDSA.",
year = "2011",
month = oct,
day = "1",
doi = "10.1093/cid/cir625",
language = "English (US)",
volume = "53",
pages = "617--630",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "7",
}